Analysis of therapeutic efficacy of Aredia in treating pain caused by advanced malignant metastatic bone tumors

Objective To study therapeutic efficacy of Aredia in treating malignant metastatic bone tumors. Method 60～90 mg Aredia was administrated iv in 31 cases with malignant metastatic tumors,once each week. Results Pain in 12 cases was significantly relieved.14 cases acquired relif.Total effective rate was 83.9%.Activity ability was improved by 80.6%.No apparent toxicological and adverse effects as well as fever and cold symptoms were observed.Conclusion Aredia is a kind of ideal drugs for treatment of pain caused by malignant metastatic bone tumors.It is convenient in use and could be endured by patients.

Limb salvage surgery for malignant bone tumors of the extremities in children and adolescents

Objective： The aim of the study was to analyze the clinical features of limb salvage surgery with epiphyseal preservation in children and adolescents, and to evaluate the recurrence rate, metastasis, complications, and the joint functional results after tumor resection. Methods： Between December 1995 and January 2003, 33 cases of preserving epiphysis procedure had been done. In this group, the tumor located in distal femur in 24 cases and in proximal tibia in 9 cases. There were 23 osteosarcomas, 6 Ewing＇s sarcomas, 2 chondrosarcomas, and 2 aggressive osteoblastomas. The patients received 2-4 cycles of preoperative adjuvant chemotherapy, and another 6 cycles after surgery. The modified protocol T10 was taken. Radiography and MRI were used to determine the margins of the tumors preoperatively and histological examination was used to corroborate the evidence intraoperatively. The tumors were staged clinically. Among them, there were 2 cases in ⅠA, 2 cases in ⅠB, 17 cases in ⅡA, and 12 cases in liB. According to the MRI analysis, the metaphyseal tumors in children were classified into 3 types. Type Ⅰ, with the tumor close to but not contacting epiphyseal plate, and the distance between the two over 2 cm, was taken as absolute indication for the technique. Type Ⅱ, with the tumor near or contacting epiphysis plate, and the distance between the two less than 1 cm, was taken as relative indication for the surgery. For type Ⅲ, the tumor contacted the epiphyseal plate partially, and was over 2 cm beyond the joint. In the cohort, 18 cases were categorized as type Ⅰ, 13 as type Ⅱ, and 2 as type Ⅲ. The size of the residual epiphyseal bone segment differed after different excision protocols which were taken according to the clinical classifications. Bone defects after tumor resections were repaired with massive intercalary allograft bone, followed by internal fixation by intramedullary nails and cancellous screws. Results： Among the 33 cases, 3 cases were lost to follow up. 29 cases had complete clinical data. Postoperative follow-up was 12-72 months. Recurrences were seen in 3 cases, with one local recurrence in type Ⅲ cases one year post tumor resection, other 2 recurrences around the femoral vessels in type Ⅱ cases 15 months and 30 months after the tumor resection respectively. The recurrence rate accounted for 10.34%. Amputation was performed for the cases with recurrences. But pulmonary metastasis developed and the patients died. In this cohort, 9 cases died. Five-year survival rate constituted 57.94% demonstrated by Kaplan-Meier survival analysis. The median survival time for male patients was 64.36 months, and that for female patients was 56.00 months （P = 0.0403）. The sites, stages and types were not associated with the survival time. Four cases reported 5 complications （17.24%）. The complications included fracture of the allograft, limb length discrepancy, nerve injury, breakage of nails, and loosening of the screws. No patient reported skin necrosis, hematoma, infection, rejection to the allograft, and nonunion at the end of the follow-up. According to the functional evaluation criteria after surgical treatment of malignant tumors of the extremities introduced by Enneking, excellent functional results were reported in 11 cases, good in 13 cases, fair in 3 cases, and poor in 2 cases. The excellent or good result rate was 83%. The excision interface involved partial epiphysis in 4 cases, involved the epiphyseal plate in 8 cases. Intact epiphysis was preserved in 17 cases. Five cases with poor postoperative functional results were in types II and III. Average time of bone union was 2.5 months for epiphyseal end and 3.8 months for diaphyseal end. According to the International Society of Limb Salvage （ISOLS） radiological implants evaluation system, excellent reconstruction was observed in 23 cases, good reconstruction in 4 cases, fair reconstruction in 1 case, and poor reconstruction in 1 case. All patients in the group had satisfactory joint stability. No patient reported joint dislocation, valgus or varus deformity, and osteoarthritis. The average limb length discrepancy was 3.2 cm, ranging 2-6 cm. Conclusion： The limb salvage surgery with preservation of epiphysis for malignant bone tumors in children and adolescents guarantees the patient＇s satisfactory postoperative limb functional results. Preoperative effective adjuvant chemotherapy and prevention of postoperative complications deserve great attention.

Combined chemotherapy with Boning in the treatment of pain due to bone metasta ses from malignant tumors

Objective To investigate the effect of Boning o n pain due to bone metastases from mal ignant tumors.Method From De-cember,1998to December,2000,86pa tients with pathologically proved b one metastases from malignant tumors were randomly divided into two groups,study group(combined chemotherapy with boning),control group(simple chemotherapy).Boning(60mg )dissolved in saline solution(500ml )were given IV for consecutive 3days.Then 60mg Boning was given every half-month .Patients in control group accepted simple chemotherapy.Results Efficacy in study group was 88.37%which was significantly superior to th at in control group(66.47%).Boning could repair injured bone.Adverse r eaction associated with Boning was weak.Boning quickly relieved sympto ms for a long time.Conclusion Effect of large-dose Boning for reli eving pain due to bone metastases fro m malignant tumors is satisfying.At the same time,Boning play im-portant role in repair of destructed bone.

Malignant giant cell tumors of the tendon sheath of the right hip:A case report

BACKGROUND Malignant giant cell tumor of the tendon sheath(MGCTTS)is an extremely rare malignant tumor originating from synovial and tendon sheath tissue with highly aggressive biological behavior and a high rate of local recurrence and distant metastasis which should be considered a highly malignant sarcoma and managed aggressively.How to systemically treat MGCTTS remains a challenge.In this case,a patient with MGCTTS suffered a recurrence after 2 surgical resections received adjuvant chemotherapy and radiation therapy,but the treatment outcome remained poor.More clinical trials and better understanding of the biology and molecular aspects of this subtype of sarcoma are needed while novel medicines should be developed to efficiently target particular pathways.CASE SUMMARY A 52-year-old man presented with persistent dull pain in the right groin accompanied by limited right hip motion starting 6 mo ago.Two months before his attending to hospital,the patient’s pain worsened,presenting as severe pain when standing or walking,limping,and inability to straighten or move the right lower extremity.Surgical excision was performed and MGCTTS was confirmed by pathology examination.Two recurrences occurred after surgical resection,moreover,the treatment outcome remained poor after adjuvant chemotherapy and radiation therapy.The patient died only 10 mo after the initial diagnosis.CONCLUSION MGCTTS is characterized by a joint mass with pain and limited motion.It typically grows along the tendons and infiltrated into the surrounding muscle and bone tissue,with a stubborn tendency to relapse,as well as pulmonary metastasis.Radically surgical resection provides a choice of treatment whereas post-operation care should be taken to preserve the function of the joint.Chemotherapy and radiotherapy can be used as alternative treatments when radical resection cannot be performed.

Imaging appearance of bone tumors of the maxillofacial region

This paper reviews the imaging appearance of benign and malignant bone tumors of the maxillofacial region.A benign bone tumor commonly appears as a well circumscribed lesion.The matrix of the tumor may be calcified or sclerotic.Malignancies often display aggressive characteristics such as cortical breakthrough, bone destruction,a permeative pattern and associated soft-tissue masses.Computed tomography scan is an excellent imaging modality for accurate localization of the lesion,characterization of the tumor matrix and detection of associated osseous changes such as bone remodeling,destruction or periosteal reaction.Magnetic resonance imaging is of limited value in the evaluation of maxillofacial bone tumors.

Clinicopathological Correlation of Primary Malignant Bone Tumors—An Observational Study

Background: Primary malignant tumors arising from bone are uncommon but important malignant neoplasms which account for 0.2% of all primary cancers in adults and approximately 5% of all childhood malignancies. Aim: No comprehensive surveillance data about primary malignant bone tumors is available from this region of West Bengal in the literature. An attempt is undertaken to correlate clinicopathological findings, both histological & cytological features of primary bone tumours. Method: This observational study of clinical presentation was corroborated with cytology and histopathology of 67 cases of primary malignant bone tumors in 2005-2007 in a tertiary health care centre. Results: Among the primary malignant tumors, 39 cases (58.20%) were male and 28 (41.80%) were female. Sixty one lesions (91%) were located in the long bones and 6 (9%) involving flat and short bones. Osteosarcomas are found to be the predominant primary malignant bone tumors (44.77%), followed by Ewing’s sarcomas (20.89%), chondrosarcomas (13.43%), high grade giant cell tumor, and plasmacytoma (5.97%). Predilection for male (M: F 2:1) found in both osteosarcoma and chondrosarcoma, but it was reverse in cases of Ewing’s sarcomas. Conclusion: Osteosarcoma is the most common around knee joint and chondrosarcoma is frequent in long bones in this region. We made an attempt to correlate FNAC findings with the histopathology and it was seen that overall sensitivity of FNAC of primary malignant bone tumors was 56.71%.

Malignant peripheral nerve sheath tumor with hemophilic syndrome and bone marrow fibrosis:A rare case report

BACKGROUND Malignant schwannoma is a rare tumor in the peripheral nervous system,accounting for approximately 5%to 10%of systemic soft tissue sarcomas.Especially,malignant schwannoma occurring in the broad ligament of the uterus with hemophilic syndrome and bone marrow fibrosis is extremely rare in clinical practice.Here,we report the first case of an patient diagnosed with malignant peripheral nerve sheath tumor(MPNST)of the broad ligament of the uterus with hemophilic syndrome and bone marrow fibrosis,and share our reference clinical diagnosis and treatment experience.CASE SUMMARY A patient was diagnosed with MPNST of the uterus harboring hemophilic syndrome and bone marrow fibrosis.She received combination,and repeated imaging revealed further encountered rare complications(hemophilia syndrome and bone marrow fibrosis)after two cycles of chemotherapy.Thereafter,combined treatment with pazopanib,gemcitabine,and dacarbazine was initiated.Unfortunately,the patient succumbed to death at hospital after two weeks.CONCLUSION This report firstly provided reference clinical practice for a patient with MPNST of the uterus harboring hemophilic syndrome and bone marrow fibrosis.Our case raises a reminder about the tolerance and safety of combination therapy,especially in young women.

Primary Malignant Giant Cell Tumor of Bone:A Case Report

Primary malignant giant cell tumor of bone is clinically rare,lack of specificity,and often misdiagnosed.Currently,related literature about this tumor remains scarce.One case of primary malignant giant cell tumor of bone was diagnosed and treated in our hospital,and the treatment effect was satisfactory.There was no recurrence or metastasis in 2 years of followup.The report is as follows.

Differentiation of malignant and benign lesions of the osseous spinal axis with three dimensional computed tomography image appearences: dirty interface sign

Purpose: We aimed to make a fast and accurate distinction of malignant and benign lesions in cases with predominantly solitary or multifocal involvement using latest technology software and hardware systems in computed tomography. Materials and Methods: 53 cases were included in the study. Primary (n = 42, 31 benign, 11 malignant) or metastatic (n = 11) tumors were detected at various locations in the bone structure of the cervical to coccygeal vertebrae in all cases. 3D CT images taken using the same system and biopsy or post-operative histopathology findings were available for all cases. Thin section images taken retrospectively from the archives were converted to 3D images using the same program and parameters, which were then recorded in the same window settings by two radiologists. Only 3D images were then analyzed to investigate the presence or absence of the dirty interface sign. Results: Dirty interface sign was present in 17 malignant lesions and absent in the remaining 5 lesions. As for benign lesions, the sign was present in only two lesions and the remaining 29 were negative for the sign. There was a high level of consistency between the two radiologists. In conclusion, malignant and benign lesions affecting the bone spinal axis were distinguished based on the presence or absence of the dirty interface sign with 77.3% sensitivity, 93.5% specificity and 86.8% accuracy. Conclusion: When evaluated with standard bone window views, 3D views can be used successfully for the distinction of malignant and benign bone tumors. At least, 3D views generated using low dose regimes in highly developed systems can be used with similar purpose to that of diffusion weighted MRI sequences that give roughly outlined but fast and accurate information about the lesion.

UNAMPUTATED TREATMENT FOR MALIGNANT BONE TUMOR AT LIMBS WITH INTERNAL RESECTION，CURETTAGE AND DEACTIVATION

A new operating programme was designed by us, based on keeping the whole limb in 1988. A successful operation on one patient with this new method was achieved on Dec. 17 in the same year at the First Teaching Hospital, Xi'an Medical Nniversity. Firstly, the internal tumor tissue was resected and curstted thoroughly, and the osseous shell was kept to attach to the normal bone tissue. Then, a plastic bag was used to encase the osseous shell in, deactivation was done with 95 per cent alcohol. the remainder osseous shell was used as a support, a pulp canal steel needle was inserted into it, and the bone cement was filled up in. In this way, a ' prosthesis' in pulp canal was formed, which was not only firm, reliable, less expensive convenient for drawing material, and satisfactory for achieving the goal of treating the tumor and keeping the limb, but also easy to move for the patient and to recover the function of the limb rapidly after operation because of not amputating the normal bone tissue and partly keeping the continuity of it. Now 25 cases have been treated with this new method, and in 90 per cent patients, the limbs have been preserved.

Reconstruction Using a Free Vascularized Fibular Graft after Frozen Autograft Reconstruction for Osteosarcoma of the Distal Tibia: A Case Report

Recently we have been performing biological reconstruction for malignant bone tumors of the extremities using frozen autografts. Here we present a case treated with free vascularized fibular graft (FVFG) after this method. A 23-year-old man developed osteosarcoma in his left distal tibia. There was nonunion after frozen autograft reconstruction, which we treated with FVFG. Twenty-four months later, bridging between the host bone and the frozen autograft was achieved. Our department has achieved bone union in almost all cases, but we sometimes encounter cases of nonunion after this method because of delayed blood supply. In these instances, reconstruction using FVFG may represent an attractive choice for salvage treatment.

补肾中药联合双膦酸盐治疗恶性肿瘤骨转移有效性及安全性的Meta分析

目的系统评价补肾中药联合双膦酸盐类药物治疗恶性肿瘤骨转移的有效性及安全性,以期为临床治疗提供参考。方法通过检索CNKI、CBM、VIP、Wanfang Data等数据库,检索时间为所有数据库建库至2023年5月5日,筛选补肾中药联合双膦酸盐类药物治疗恶性肿瘤骨转移的随机对照临床试验,使用Cochrane偏倚风险评估工具对纳入的文献质量进行评估,并采用Rev Man 5.3软件对纳入研究进行Meta分析。结果共纳入18项临床研究,总样本量为1213例,其中对照组594例,治疗组619例。治疗组患者骨转移无进展生存时间、骨转移病灶疗效、止痛效果、数字化评估量表(NRS)疼痛评分、Karnofsky功能状态评估表(KPS)评分、活动能力、血钙水平及不良反应发生情况均优于对照组,差异均有统计学意义(P<0.05)。2组患者治疗前后碱性磷酸酶水平差异无统计学意义(P>0.05)。结论补肾中药联合双膦酸盐类药物可以抑制骨转移病灶进展,减轻骨转移引起的疼痛,改善患者生活质量及活动能力,并且可以降低血钙水平及不良反应发生率,证明从肾论治恶性肿瘤骨转移有一定的临床意义。

以骨肉瘤形态为主的原发性恶性骨巨细胞瘤7例临床病理分析

目的探讨以骨肉瘤形态为主原发性恶性骨巨细胞瘤(primary malignant giant cell tumor of bone,PMGCTB)的临床病理学特征。方法回顾性分析7例PMGCTB的临床病理特征。结果7例PMGCTB中,女性4例,男性3例,年龄9~66岁(平均39.5岁,中位年龄35岁)。发生部位以股骨骨端最常见(3/6),临床表现为病变部位的疼痛和肿胀。影像学表现为溶骨性占位、溶骨和硬化混合性占位为主;多数骨皮质破坏伴软组织肿块形成(5/7)。组织学均以普通型骨肉瘤形态为主,破骨细胞样多核巨细胞完全消失或少量存在。免疫表型:6例肿瘤细胞H3F3A G34W核阳性、1例H3F3A G34V核阳性,所有肿瘤均表达SATB2、p63,p53呈野生型,Ki67增殖指数10%~50%。所有病例均发现H3F3A基因改变,6例为H3F3A p.G34W突变,1例为H3F3A p.G34V突变。结论PMGCTB罕见,当缺乏经典骨巨细胞瘤组织学特征时诊断更具挑战性,需结合影像学、免疫表型及分子检测,并注意与骨肉瘤及其他高级别肉瘤相鉴别。

紫杉醇、唑来膦酸配合治疗恶性骨肿瘤的疗效分析

目的 对恶性骨肿瘤患者使用紫杉醇、唑来膦酸配合治疗的效果进行分析。方法 84例恶性骨肿瘤患者,采用随机抽样法分为常规组和研究组,每组42例。常规组采用紫杉醇进行治疗,研究组采用紫杉醇、唑来膦酸配合治疗。对比两组患者的疗效、不良反应发生情况、镇痛效果、疼痛程度、生活质量、血常规指标、血清癌胚抗原和血钙水平。结果 研究组总有效率95.24%高于常规组的78.57%(P<0.05)。研究组不良反应发生率4.76%低于常规组的23.81%(P<0.05)。研究组镇痛总有效率92.86%高于常规组的76.19%(P<0.05)。研究组治疗后3、6、12个月视觉模拟评分法(VAS)评分分别为(1.24±0.62)、(1.25±0.41)、(0.65±0.33)分,均低于常规组的(3.65±1.34)、(2.67±1.68)、(2.35±1.46)分(P<0.05)。治疗后,研究组社会功能、躯体功能、物质功能、心理功能评分分别为(79.81±7.26)、(87.69±7.45)、(85.41±6.28)、(85.37±7.69)分,均高于常规组的(70.21±6.24)、(75.31±6.58)、(74.24±6.85)、(77.15±7.08)分(P<0.05)。治疗后,研究组白细胞计数、血红蛋白、血小板计数分别为(7.20±1.21)×10^(9)/L、(126.78±12.26)g/L、(145.47±23.74)×10^(9)/L,均高于常规组的(5.39±2.29)×10^(9)/L、(100.25±13.17)g/L、(118.47±30.25)×10^(9)/L(P<0.05)。治疗后,研究组血清癌胚抗原、血钙水平分别为(35.54±11.60)ng/ml、(2.16±0.20)mmol/L,低于常规组的(44.42±11.65)ng/ml、(2.47±0.64)mmol/L(P<0.05)。结论 为恶性骨肿瘤患者使用紫杉醇、唑来膦酸配合治疗,可以减轻患者疼痛程度,镇痛效果良好,且可改善患者血常规指标及血清癌胚抗原、血钙水平,患者不良反应少,生活质量显著提高,疗效明显,可大力推广。

徐经世国医大师治疗恶性肿瘤骨转移临床用药经验探析

总结介绍徐经世国医大师治疗恶性肿瘤骨转移临床用药经验。徐经世国医大师认为晚期恶性肿瘤骨转移的基本病机为正气亏虚、肾精不足,后因癌邪侵袭、病久阳气亏虚致痰瘀互结、寒湿凝滞。骨转移以本虚标实为主,在临床辨证用药上以益气扶正、补肾壮骨为主,辅以活血祛瘀、温阳通络,临床收效甚佳,可对于多种恶性肿瘤骨转移治疗提供借鉴。

鸡尾酒疗法联合连续股神经阻滞在膝关节周围恶性骨肿瘤患者术后镇痛中的应用效果

目的:观察鸡尾酒疗法联合连续股神经阻滞(FNB)在膝关节周围恶性骨肿瘤患者术后镇痛中的应用效果。方法:选取2020年9月至2022年9月于该院行全膝关节置换术(TKA)的107例膝关节周围恶性骨肿瘤患者进行前瞻性研究,采用随机数字表法将其分为对照组53例和观察组54例。对照组术后给予FNB镇痛,观察组在对照组基础上联合鸡尾酒疗法镇痛,比较两组术后疼痛程度[被动活动视觉模拟评分表(PVAS)、静息状态视觉模拟评分表(RVAS)]评分、下肢微循环指标[足背动脉血流量、踝肱指数(ABI)]水平和血清炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、C反应蛋白(CRP)]水平。结果:观察组术后24、48 h的RVAS、PVAS评分均低于对照组,差异有统计学意义(P<0.05);术后48 h,两组足背动脉血流量、ABI均低于术前,但观察组高于对照组,差异有统计学意义(P<0.05);术后48 h,两组TNF-α、IL-6、CRP水平均高于术前,但观察组低于对照组,差异有统计学意义(P<0.05)。结论:鸡尾酒疗法联合FNB应用于膝关节周围恶性骨肿瘤患者术后镇痛可提高下肢微循环指标水平,降低RVAS评分、PVAS评分和血清炎性因子水平,效果优于单纯FNB镇痛。

基于多学科的护理干预对恶性骨肿瘤患者截肢术后幻肢痛、负性情绪和睡眠质量的影响

目的:探讨基于多学科的护理干预对恶性骨肿瘤患者截肢术后幻肢痛、负性情绪和睡眠质量的影响。方法:选取80例实施截肢术的恶性骨肿瘤患者为研究对象,依据护理干预方式不同分为对照组和观察组,每组各40例。对照组患者予以常规护理干预;观察组予以多学科护理干预,两组患者均干预至术后7 d。比较两组患者疼痛情况[视觉模拟疼痛评分法(VAS评分)]、幻肢痛平均每日次数、负性情绪[焦虑自评量表(SAS)和抑郁自评量表(SDS)评分]及睡眠质量[匹兹堡睡眠质量指数(PSQI)评分]。结果:两组患者术后VAS评分、每日幻肢痛次数均逐渐下降(P<0.05),且观察组术后各时间点均低于对照组(P<0.05)。术后7 d,两组患者术后SAS及SDS评分、PSQI各维度评分及总分均下降(P<0.05),且观察组低于对照组(P<0.05)。结论:对恶性骨肿瘤截肢患者实施基于多学科的护理干预能有效改善患者术后幻肢痛,减轻其焦虑、抑郁等负性情绪,提升患者睡眠质量。

不同重建方式治疗四肢原发性恶性骨肿瘤的随访研究

目的通过分析原发性恶性骨肿瘤患者在瘤段切除后经不同重建方式治疗的随访资料,探讨手术方案的选择对临床疗效的影响。方法以2016年7月1日至2022年7月1日东部战区总医院单中心收治的四肢原发性恶性骨肿瘤患者为研究对象,根据瘤段切除后重建方式分为肿瘤型假体置换组和生物重建组。回顾患者的临床随访资料,对比2组患者至随访截止时间的复发率、转移率、生存率以及最终保肢率,并总结生物重建失败的影响因素。同时,采用美国肌肉骨骼肿瘤协会评分(MSTS)、多伦多保肢评分(TESS)评价并比较不同组间患者术后功能的恢复情况。结果共收集并筛选入组患者87例,其中男52例,女35例,年龄8~71岁,平均(38.3±21.2)岁。随访15~70个月,平均随访时间26.5个月。至随访截止时间,共存活67例,死亡20例,总生存率为77.01%;无瘤存活45例,无瘤生存率为51.72%。其中,假体置换组74例、生物重建组13例(瘤体骨灭活再植钢板重建2例、自体腓骨移植钢板重建11例)。生物重建组术后1年的MSTS评分及TESS评分均明显高于假体置换组(28.33±2.09 vs 24.16±4.51、85.62±6.71 vs 80.82±3.85,P<0.01)。假体置换组术后生存率达到了75.68%。而生物重建组患者术后生存率更达到了84.62%,且根据多因素Cox比例风险回归分析结果,不同的手术方式对无瘤生存(TFS)、总生存(OS)均无显著影响(P>0.05),复发和转移发生与否才是影响OS的预测因素(P=0.003和P=0.001)。而进一步的研究显示,两种不同手术方式的选择与患者的生存率(P=0.0843)、复发率(P=0.5206)、转移率(P=0.3217)无显著相关性。假体置换组与生物重建组的二次手术率(29.73%vs 38.46%)及最终保肢率(83.78%vs 84.62%)比较,差异均无统计学意义(P>0.05)。行瘤段切除后自体腓骨移植钢板重建的患者有11例,其中出现移植骨骨不连2例;愈合时间与年龄、术前肿瘤生长部位、术中截骨长度、取骨部位及植骨量均有相关性(P<0.05)。结论随着治疗理念和手术技术的不断进步,针对原发性恶性骨肿瘤瘤段切除后的骨缺损,采用术前精准测量和周密设计的生物重建手术,可以发挥其在关节稳定、肢体功能、保障疗效等各方面的优势,从而取得较假体置换手术更佳的治疗效果。

半侧骨皮质切除灭活再植术对四肢低度恶性骨肿瘤的疗效分析

目的探讨半侧骨皮质切除灭活再植术对四肢低度恶性骨肿瘤的疗效。方法选取四肢低度恶性骨肿瘤108例,依照随机数字表法划分为对照组(n=54)和研究组(n=54),对照组使用人工关节置换术,研究组使用半侧骨皮质切除灭活再植术。对比2组优良率、围术期变化、日常生活功能、肢体能力、血清因子[肿瘤坏死因子-α(TNF-α)、可溶性血管粘附分子(s VCAM-1)]、并发症发生率。结果研究组优良率[96.30%(52/54)]较对照组[72.22%(39/54)]高(P<0.05);与对照组比较,研究组手术时长、住院时长短,且术中出血量少(P<0.05);与对照组比较,术后6个月研究组日常生活功能、肢体能力分值高(P<0.05);与对照组比较,术后6个月研究组TNF-α、s VCAM-1水平低(P<0.05);研究组截肢、肌肉萎缩发生率[1.85%(1/54)、7.41%(4/54)]与对照组[5.56%(3/54)、14.81%(8/54)]比较,无显著变化(P>0.05),且研究组感染发生率[0.00%(0/54)]比对照组[16.67%(9/54)]低(P<0.05)。结论半侧骨皮质切除灭活再植应用于四肢低度恶性骨肿瘤中可以提高优良率,改善围术期变化,可下调血清因子,改善日常生活功能和肢体能力,并能降低术后感染发生风险。

伊班膦酸钠与唑来膦酸治疗恶性肿瘤骨转移患者的效果比较

目的:比较伊班膦酸钠与唑来膦酸治疗恶性肿瘤骨转移患者的效果。方法:选取2022—2023年该院收治的104例恶性肿瘤骨转移患者进行前瞻性研究,采用随机数字表法将其分为对照组和研究组各52例。对照组采用唑来膦酸注射液治疗,研究组采用伊班膦酸钠注射液治疗。比较两组骨转移灶清退效果、治疗前后癌痛程度[数字分级评分法(NRS)]评分、骨相关事件(SREs)发生率和不良反应发生率。结果:研究组骨转移灶清退总有效率为86.54%(45/52),高于对照组的67.31%(35/52),差异有统计学意义(P<0.05);治疗12、24周后,两组NRS评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);研究组SREs发生率均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:伊班膦酸钠治疗恶性肿瘤骨转移患者可提高骨转移灶清退效果,以及降低癌痛程度评分和SREs发生率的效果优于唑来膦酸注射液治疗。